An experimental vasculature-targeting peptidomimetic studied in obesity models.
Also known as: Prohibitin-TP01 · TP01 · FTPP
Part of the Metabolic & GLP-1 peptides cluster
Overview
Adipotide (Prohibitin-TP01) is an experimental chimeric peptidomimetic that pairs a homing sequence targeting adipose-tissue blood vessels with a pro-apoptotic motif. Studied in animal obesity models, its clinical development was discontinued. It is not an approved therapeutic in Canada.
Source & context
Biological / chemical source: Synthetic peptidomimetic combining a homing sequence with a pro-apoptotic motif
Primary research or clinical context: Discontinued investigational compound; not an approved drug in Canada
Targeting design
Adipotide is built as a chimeric molecule: a peptide that homes to prohibitin and ANXA2 on the blood vessels feeding white adipose tissue, fused to a KLAKLAK-type sequence intended to disrupt mitochondrial membranes. The concept was to reduce fat depots by targeting their vascular supply.
Research findings and limits
Published work reported rapid weight loss in mouse and non-human-primate models, generating substantial interest. However, development was discontinued, and human efficacy and safety were not established. Search popularity outpaces the strength of clinical evidence for this compound.
FAQ about Adipotide
What is Adipotide?+
Adipotide (Prohibitin-TP01) is an experimental chimeric peptidomimetic that pairs a homing sequence targeting adipose-tissue blood vessels with a pro-apoptotic motif. Studied in animal obesity models, its clinical development was discontinued. It is not an approved therapeutic in Canada.
Is Adipotide an approved medicine?+
Adipotide is discussed here as a research / educational topic. Discontinued investigational compound; not an approved drug in Canada. This is not medical advice.
What is the typical length of Adipotide?+
Adipotide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.